Clin Interv Aging. 2019 Mar 29;14:631-642. doi: 10.2147/CIA.S200109. eCollection 2019.
Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update.
Sumirtanurdin R1, Thalib AY1, Cantona K1, Abdulah R1,2.
Genetic variations in individuals may cause differences in the response to cholinesterase inhibitor drugs used in the treatment of Alzheimer's disease (AD). Through this review, we aimed to understand the potential relationship between genetic polymorphisms and treatment response in AD. We conducted a systematic review of the studies published from 2006 to 2018 that assessed the relationship between genetic polymorphisms and the pharmacotherapeutic outcomes of patients with AD. Via several possible mechanisms, genetic polymorphisms of many genes, including ABCA1, ApoE3, CYP2D6, CHAT, CHRNA7, and ESR1, appear to have strong correlations with the treatment response of patients with AD. Indeed, these genetic polymorphisms, either in the form of single nucleotide polymorphisms or direct changes to one or more amino acids, have been shown to cause differences in the therapeutic response. In summary, our findings indicate that genetic polymorphisms should be considered in the management of AD to achieve both effective and efficient treatment outcomes in terms of cost and prognosis.
Alzheimer’s disease; genetic polymorphisms; treatment response
No hay comentarios:
Publicar un comentario